Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 5, 2011, Pages 383-

  Smyth, Alan ^a   Knox, Alan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CREATININE; N ACETYL BETA GLUCOSAMINIDASE; TOBRAMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; NEPHROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE;

CEFTAZIDIME; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 80052513430     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.03.010     Document Type: Letter

References (6)

1. Adeboyeku D., Jones A.L., Hodson M.E. Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros 2011, 10:25-30.
2. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005, 365(9459):573-578.
3. UK Cystic Fibrosis Trust Antibiotic Group Antibiotic Treatment for Cystic Fibrosis 2009, UK Cystic Fibrosis Trust, London. 3rd ed.
4. Mulheran M., Hyman-Taylor P., Tan K.H.V., Lewis S., Stableforth D., Knox A., et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006, 50(7):2293-2299.
5. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180(9):802-808.
6. Tan K.H.-V., Hyman-Taylor P., Mulheran M., Knox A., Smyth A. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centres. Pediatr Pulmonol 2002, 33:165.